- Biologic therapy for psoriasis – protein-based infusions to suppress inflammation – was associated with a significant reduction in high-risk plaque in heart arteries, over one-year, according to new research.
- The positive association between biologic therapy and a decrease in high-risk plaque in heart arteries was significant after adjusting for cardiovascular risk factors and psoriasis severity.
Embargoed until 4 a.m. CT/5 a.m. ET Tuesday, September 15, 2020
DALLAS, September 15, 2020 — Patients with psoriasis treated with biologic therapy, which are protein-based infusions to suppress inflammation, had a significant reduction in high-risk plaque in heart arteries, over one-year, according to new research published today in Circulation: Cardiovascular Imaging, an American Heart Association journal.
Chronic inflammation in people with psoriasis is associated with a higher risk of developing coronary artery disease. Biologic therapy medications are proteins that are given by injection or infusion and suppress the inflammation process by blocking the action of cytokines, which are proteins that promote systemic inflammation.
Previous research has shown a clear link between psoriasis and the development of high-risk coronary plaque. This study provides characterization of a lipid-rich necrotic core, a dangerous type of coronary plaque made up of dead cells and cell debris that is prone to rupture. Ruptured plaque can lead to a heart attack or stroke.
“Having inflamed plaque that is prone to rupture increases the risk of heart attack five-fold within ten years,” said Nehal N. Mehta, M.D., M.S.C.E., FAHA, study senior author, a Lasker Senior Investigator and chief of the Lab of Inflammation and Cardiometabolic Diseases at the National Heart, Lung, and Blood Institute at the National Institutes of Health in Bethesda, Maryland.
“This is the first time an imaging study in humans has shown what one year of ongoing, untreated inflammation can do to arteries of the heart and that we can reverse this damage. Untreated inflammation is dangerous. You are just waiting for a heart attack or stroke to happen,” Mehta said.
The analysis involved 209 middle-aged patients (ages 37-62) with psoriasis who participated in the Psoriasis Atherosclerosis Cardiometabolic Initiative at the National Institutes of Health, an ongoing observational study. Of these participants, 124 received biologic therapy, and 85 were in the control group, treated only with topical creams and light therapy.
To measure the effects of biologic therapy on arteries of the heart, the researchers performed cardiac computed tomography (CT) scans on all study participants before they started therapy and one year later. The CT results between the two groups were then compared.
At the start of the study, participants with psoriasis had low cardiovascular risk by conventional cardiovascular risk scores, and severe psoriasis was associated with higher body mass index (BMI), high-sensitivity C-reactive protein (a measure of systemic inflammation) and higher levels of coronary artery plaque.
After one year of treatment, patients who received biologic therapy were compared to the control group. Researchers found:
- Biologic therapy was associated with an 8% reduction in coronary plaque. In contrast, those in the control group experienced slightly increased coronary plaque progression.
- Even after adjusting for cardiovascular risk factors and psoriasis severity, patients treated with biologic therapy had reduced coronary plaque.
“There is approximately 6-8% reduction in coronary plaque following therapy with statins. Similarly, our treatment with biologic therapy reduced coronary plaque by the same amount after one year. These findings suggest that biologic therapy to treat psoriasis may be just as beneficial as statin therapy on heart arteries,” Mehta said.
This study has implications for people with psoriasis and possibly for people with other chronic inflammatory conditions such as HIV, lupus and rheumatoid arthritis, who also have increased risk of heart disease.
“We have never before been able to show healing of an inflamed plaque like this in humans. Biologic therapy reduces systemic inflammation and immune activation, and it has a favorable impact on improving overall vascular health,” Mehta said. “Imagine if we can treat both psoriasis and coronary heart disease with one therapy – that is the question to be asked in future studies.”
The study’s findings should be interpreted with caution because it was limited by a short follow-up period and a relatively small number of patients. Larger, randomized controlled studies are needed to better understand how changes in coronary plaque may lead to a reduction in heart attacks and strokes in people with psoriasis.
Co-authors are Harry Choi, M.D.; Domingo E. Uceda, B.S.; Amit K. Dey, M.D.; Khaled M. Abdelrahman, B.S.; Milena Aksentijevich, M.Sc.; Justin A. Rodante, PA-C; Youssef A. Elnabawi, M.D.; Aarthi Reddy, B.S.; Andrew Keel, R.N.; Julia Erb-Alvarez, M.P.H.; Heather Teague, Ph.D. Martin P. Playford, Ph.D.; Wunan Zhou, M.D., M.P.H.; Marcus Y. Chen, M.D.; Joel M. Gelfand, M.D., M.S.C.E; David A. Bluemke, M.D., Ph.D.; and Andrew Buckler, M.S. Author disclosures are in the manuscript.
This study was funded by the National Heart, Lung, and Blood Institute (NHLBI) Intramural Research Program and the NIH Medical Research Scholars Program at the National Institutes of Health.
- Available multimedia is on right column of release link - https://newsroom.heart.org/news/biologic-therapy-for-psoriasis-may-reduce-heart-disease?preview=7316791ebf1ca823f294a602a9447e52
- After September 15, view the manuscript online.
- Plaque in arteries may not all be the same; targeting specific immune cells in plaque may reduce heart attack and stroke risk
- Inflammation and Heart Disease
- Follow AHA/ASA news on Twitter @HeartNews
- Follow news from the AHA’s Circulation: Cardiovascular Imaging journal @CircImaging
Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations and health insurance providers are available at https://www.heart.org/en/about-us/aha-financial-information
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.
For Media Inquiries and AHA/ASA Expert Perspective: 214-706-1173
Karen Astle: 214-706-1392, email@example.com
For Public Inquiries: 1-800-AHA-USA1 (242-8721)
heart.org and stroke.org